Heron Therapeutics, Inc.
HRTXNASDAQHealthcare● Active
$0.45
+$0.03(+6.13%)
Market Cap$71641543
P/E Ratio—
52W High$2.3
52W Low$0.42
Heron Therapeutics, Inc. (HRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HRTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.04
Est. -$0.03 · -33.3%
Revenue
$0.03B
Est. $0.04B · -5.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
HRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.02 | — | — | — | $0.04B | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.03 | -$0.04 | -33.3% | $0.03B | $0.04B | -5.5% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.03 | -$0.02 | +33.3% | $0.04B | $0.04B | +1.8% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.01 | -$0.05 | -275.1% | $0.04B | $0.04B | -2.1% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -$0.01 | -$0.02 | -100.0% | $0.04B | $0.04B | -4.8% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.01 | $0.01 | +200.0% | $0.04B | $0.04B | +1.7% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.03 | $0.02 | +166.7% | $0.04B | $0.04B | +11.2% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.03 | -$0.03 | -9.1% | $0.04B | $0.04B | +13.1% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.04
EPS Est.
-$0.03
EPS Surpr.
-33.3%
Revenue
$0.03B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.03
EPS Surpr.
+33.3%
Revenue
$0.04B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.05
EPS Est.
-$0.01
EPS Surpr.
-275.1%
Revenue
$0.04B
Q3 FY2025
Aug 8, 2025Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-100.0%
Revenue
$0.04B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.01
EPS Surpr.
+200.0%
Revenue
$0.04B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.03
EPS Surpr.
+166.7%
Revenue
$0.04B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.03
EPS Est.
-$0.03
EPS Surpr.
-9.1%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2026 | $-0.01 | $-0.00 | $-0.00 | 1 |
| Q1 FY2026 | $-0.03 | $-0.02 | $-0.02 | 1 |
| Q4 FY2025 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2025 | $-0.02 | $-0.01 | $-0.01 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -33.3% | $1.21 | $0.96 | -21.05% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +33.3% | $1.08 | $1.20 | +11.11% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -275.1% | $1.18 | $1.14 | -3.39% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -100.0% | $1.84 | $1.32 | -28.26% |
| ▲ Q2 FY2025 | May 6, 2025 | +200.0% | $2.13 | $2.42 | +13.62% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +166.7% | $1.71 | $2.05 | +19.88% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -9.1% | $1.84 | $1.28 | -30.43% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -50.0% | $2.63 | $2.67 | +1.52% |
Q2 FY2026-21.05%
Report Date
May 11, 2026
EPS Beat/Miss
-33.3%
Price Before
$1.21
Price After
$0.96
Q1 FY2026+11.11%
Report Date
Feb 26, 2026
EPS Beat/Miss
+33.3%
Price Before
$1.08
Price After
$1.20
Q4 FY2025-3.39%
Report Date
Nov 4, 2025
EPS Beat/Miss
-275.1%
Price Before
$1.18
Price After
$1.14
Q3 FY2025-28.26%
Report Date
Aug 8, 2025
EPS Beat/Miss
-100.0%
Price Before
$1.84
Price After
$1.32
Q2 FY2025+13.62%
Report Date
May 6, 2025
EPS Beat/Miss
+200.0%
Price Before
$2.13
Price After
$2.42
Q1 FY2025+19.88%
Report Date
Feb 27, 2025
EPS Beat/Miss
+166.7%
Price Before
$1.71
Price After
$2.05
Q4 FY2024-30.43%
Report Date
Nov 12, 2024
EPS Beat/Miss
-9.1%
Price Before
$1.84
Price After
$1.28
Q3 FY2024+1.52%
Report Date
Aug 6, 2024
EPS Beat/Miss
-50.0%
Price Before
$2.63
Price After
$2.67
Avg Beat Reaction+14.87%
Avg Miss Reaction-16.32%
Beat Rate3 / 8 quarters
Largest Move-30.43% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HRTX ends December
Heron Therapeutics, Inc. (HRTX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.04 — missing the analyst consensus of $-0.03 by -33.3%. The next HRTX earnings date is expected around September 1, 2026.
Each quarter, investors track HRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HRTX earnings · 5 questionsHeron Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. HRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HRTX historically reports after market close (AMC).
HRTX earnings datewhen is HRTX earningsHRTX next earnings datewhen does HRTX report earningsHRTX earnings calendar
▸ Source: FMP · Heron Therapeutics, Inc. SEC filings · US GAAP · Heron Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026